{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:31:33Z","timestamp":1793205093847,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007492","name":"Fondation Bettencourt Schueller","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:47:11Z","timestamp":1772772431000},"page":"1172-1179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-5895","authenticated-orcid":false,"given":"Marc","family":"Scherlinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Dieudonn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Hilliquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Chatelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"d\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Gies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Nespola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestine","family":"Simand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"El Aatmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Laure","family":"Brandely-Piat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Sebbag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Decroocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.02.002_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.933468","article-title":"Role of B-cell in the pathogenesis of systemic sclerosis","volume":"13","author":"Thoreau","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.02.002_bib0002","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.02.002_bib0003","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.002_bib0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.ard.2026.02.002_bib0006","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.002_bib0007","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/annrheumdis-2018-214382","article-title":"Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib","volume":"78","author":"Ricard","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.02.002_bib0008","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.02.002_bib0009","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41573-025-01242-0","article-title":"Advances in the treatment of systemic lupus erythematosus","volume":"24","author":"Scherlinger","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ard.2026.02.002_bib0010","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.02.002_bib0011","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.02.002_bib0012","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ard.2026.02.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ard.2026.02.002_bib0015","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.02.002_bib0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ard.2026.02.002_bib0017","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cyto.2018.10.023","article-title":"Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies","volume":"113","author":"Pescarmona","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.ard.2026.02.002_bib0018","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2665-9913(24)00403-X","article-title":"Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study","volume":"7","author":"Hinchcliff","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.02.002_bib0019","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/annrheumdis-2024-eular.2775","article-title":"Ab1163 Type 1 interferon signature in systemic sclerosis","volume":"83","author":"Allanore","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.002_bib0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","article-title":"Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation","volume":"84","author":"Siegert","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.002_bib0021","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:16:38Z","timestamp":1780323398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003496726000774"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.002","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}